BioLab Holdings Teams Up with SweetBio to Enhance Wound Care Solutions in the U.S.
BioLab Holdings, Inc., a medical technology firm based in Phoenix, has recently announced a significant partnership with SweetBio®, a biotechnology company recognized for its bioengineered wound care products. This strategic alliance aims to enhance the availability and accessibility of SweetBio's APIS® wound care solutions, which integrate collagen and medical-grade Mānuka honey to effectively handle both acute and chronic wounds.
The collaboration builds upon SweetBio's earlier partnerships, particularly with Resolve Medical, and now extends to BioLab’s extensive national distribution network. The partnership’s primary goal is to expedite the adoption of SweetBio's innovative wound care solutions among healthcare providers across various clinical settings, ensuring that these advanced products reach those who need them most.
APIS® wound coverings, a flagship offering from SweetBio, significantly bolster BioLab's commitment to a comprehensive continuum of care. This innovative product is engineered for a diverse range of clinical applications, providing healthcare professionals with the necessary flexibility to customize treatments based on individual patient needs and wound types. As the first wound care product to merge UMF-certified Mānuka honey, collagen derivatives, and hydroxyapatite, APIS® is crafted for effectiveness at every stage of the healing process—from early bacteria reduction and inflammation management to the phases of proliferation and remodeling.
Jaime Leija, BioLab’s president, emphasized the company's dedication to advancing care standards with efficient technology solutions. He stated, We aim to identify what works best and expedite its availability to clinicians, highlighting the importance of their partnership with SweetBio in expanding their product offerings. This collaboration reflects BioLab's overarching mission to deliver impactful solutions to healthcare providers, thereby improving patient outcomes.
SweetBio's portfolio currently holds Medicare coverage, making its products accessible in diverse healthcare environments, including outpatient clinics and specialized wound care centers within hospitals. Clinical studies published in respected peer-reviewed journals have shown that SweetBio's products significantly reduce the time needed for wound closure, enhancing comfort for patients dealing with chronic ulcers and surgical wounds.
Kayla Rodriguez Graff, Co-Founder and CEO of SweetBio, expressed that the company’s mission centers around streamlining the journey to wound closure through innovative materials that are both effective and straightforward for clinicians to use. She noted, Built on the same foundational technology as our initial product, VERIS™, APIS® aims to bring proven science directly into clinical settings. The collaboration with BioLab is expected to drive SweetBio’s growth while aligning with a team that remains dedicated to enhancing patient healthcare outcomes.
This partnership exemplifies BioLab’s ongoing investment in bioengineered technologies and regenerative medicine, ultimately focusing on ensuring continuity of care and broadening therapeutic choices available to clinicians managing complex wounds. By leveraging its robust distribution capabilities, BioLab is poised to support SweetBio in solidifying a stronger presence in the U.S. market, ensuring that innovative wound care solutions are effectively delivered to those in need.
For more details on BioLab Holdings and their continuum of care initiatives, visit their website at biolabholdings.com. To find out more about SweetBio's innovative products, head over to sweetbio.com.
The collaboration builds upon SweetBio's earlier partnerships, particularly with Resolve Medical, and now extends to BioLab’s extensive national distribution network. The partnership’s primary goal is to expedite the adoption of SweetBio's innovative wound care solutions among healthcare providers across various clinical settings, ensuring that these advanced products reach those who need them most.
APIS® wound coverings, a flagship offering from SweetBio, significantly bolster BioLab's commitment to a comprehensive continuum of care. This innovative product is engineered for a diverse range of clinical applications, providing healthcare professionals with the necessary flexibility to customize treatments based on individual patient needs and wound types. As the first wound care product to merge UMF-certified Mānuka honey, collagen derivatives, and hydroxyapatite, APIS® is crafted for effectiveness at every stage of the healing process—from early bacteria reduction and inflammation management to the phases of proliferation and remodeling.
Jaime Leija, BioLab’s president, emphasized the company's dedication to advancing care standards with efficient technology solutions. He stated, We aim to identify what works best and expedite its availability to clinicians, highlighting the importance of their partnership with SweetBio in expanding their product offerings. This collaboration reflects BioLab's overarching mission to deliver impactful solutions to healthcare providers, thereby improving patient outcomes.
SweetBio's portfolio currently holds Medicare coverage, making its products accessible in diverse healthcare environments, including outpatient clinics and specialized wound care centers within hospitals. Clinical studies published in respected peer-reviewed journals have shown that SweetBio's products significantly reduce the time needed for wound closure, enhancing comfort for patients dealing with chronic ulcers and surgical wounds.
Kayla Rodriguez Graff, Co-Founder and CEO of SweetBio, expressed that the company’s mission centers around streamlining the journey to wound closure through innovative materials that are both effective and straightforward for clinicians to use. She noted, Built on the same foundational technology as our initial product, VERIS™, APIS® aims to bring proven science directly into clinical settings. The collaboration with BioLab is expected to drive SweetBio’s growth while aligning with a team that remains dedicated to enhancing patient healthcare outcomes.
This partnership exemplifies BioLab’s ongoing investment in bioengineered technologies and regenerative medicine, ultimately focusing on ensuring continuity of care and broadening therapeutic choices available to clinicians managing complex wounds. By leveraging its robust distribution capabilities, BioLab is poised to support SweetBio in solidifying a stronger presence in the U.S. market, ensuring that innovative wound care solutions are effectively delivered to those in need.
For more details on BioLab Holdings and their continuum of care initiatives, visit their website at biolabholdings.com. To find out more about SweetBio's innovative products, head over to sweetbio.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.